新的模型揭示了慢性肾病患者的死亡人数不断上升, planet and economies

IMPACT CKD模型项目多达16个.5% of the population across eight countries to suffer from chronic kidney disease by 2032

澳门葡京网赌游戏(AstraZeneca)的一项新模型分析IMPACT CKD预测，死亡人数将达到16人.5% of the population across eight countries will suffer from chronic kidney disease (CKD) by 2032, 包括上升到59.3% in advanced-stage.¹ 在布宜诺斯艾利斯举行的2024年ISN世界肾脏学大会(WCN ' 24)上发表, the study highlights an urgent and growing global health crisis with profound economic and environmental implications.¹ 影响CKD是第一个研究和预测巨大的, multi-dimensional impact of CKD over a 10-year time horizon across eight countries — the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia.¹

The research estimates nearly 125 million people across these countries will suffer from advanced CKD by 2032, 自2022年该模型开始以来，这一数字增长了25%.¹ 肾脏替代疗法的经济代价, 包括透析和移植, 预计将达到1860亿美元左右, 透析需求预计将激增75%以上, contributing significantly to healthcare's carbon footprint — equivalent to adding approximately 17.相当于300万辆汽车的二氧化碳排放量.¹

Ruud Dobber, Executive Vice-President, 澳门葡京赌博游戏事业部, AstraZeneca, 强调:“澳门葡京赌博游戏的模型强调了慢性肾病对患者的巨大影响, 经济与环境. 但这样的未来并非不可避免. At AstraZeneca, we are committed to working with global policy makers to reduce the world-wide impact of end-stage CKD and drive earlier diagnosis and treatment to slow or halt progression of disease.”

The IMPACT CKD study is part of AstraZeneca’s Accelerating Change Together (ACT) for CKD initiative, 旨在提高全球对慢性肾病的认识和疗效. 通过ACT CKD项目, AstraZeneca, 与全球肾脏健康患者联盟(GloPAKH), has launched ‘为肾脏健康做出改变’ campaign. 这一倡议旨在提升慢性肾病在全球政策议程上的地位, advocating for comprehensive and effective disease management strategies to combat this escalating health challenge.

Notes

CKD  
CKD is a serious, progressive condition defined by decreased kidney function (shown by reduced eGFR or markers of kidney damage, or both, 至少三个月).² 全球有近8.5亿人患有慢性肾病，³ 大多数人没有得到诊断.² 慢性肾脏病最常见的病因是糖尿病、高血压和肾小球肾炎^.4 CKD is associated with significant patient morbidity and an increased risk of cardiovascular (CV) events, 如心力衰竭(HF), 导致过早死亡.⁵ In its most severe form, known as kidney failure, kidney damage and deterioration of kidney function have progressed to the point where dialysis or kidney transplantation are required^.6 The majority of patients with CKD will die from CV causes before reaching kidney failure^.7 

IMPACT CKD
IMPACT CKD is an innovative study that incorporates a sophisticated simulation model to unveil a holistic projection of the extensive impacts of chronic kidney disease (CKD) across clinical, economic, societal, 以及环境因素.¹ 这个具有里程碑意义的分析提供了第一个, CKD影响的10年展望, 为美国提供洞察力, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China, and Australia.¹ 强调CKD早期发现和治疗的重要性, the study offers strategic insights aimed at substantially mitigating the disease's multi-dimensional burden.¹

ACT on CKD
ACT on CKD is a programme by AstraZeneca to transform kidney health through partnerships aimed at reducing the proportion of patients progressing to kidney failure by 20% by 2025. To realise this ambition, the programme supports initiatives that aim to raise awareness of the burden of CKD and its consequences, expand early detection and drive optimisation of treatment to improve patient outcomes. 进一步支持有慢性肾病风险的人群, 澳门葡京赌博游戏还希望通过卫生政策改革实现可持续变革. 

澳门葡京赌博游戏想提供病人, healthcare providers (HCPs) and decision makers with the necessary information to drive change. As a part of our broader contribution to building knowledge around CKD we continue to generate evidence to help advance clinical practice: DISCOVER-CKD shows a lack of urine albumin-creatinine ratio (UACR) testing and adherence to Kidney Disease Improving Global Outcomes (KDIGO) guidelines; REVEAL-CKD shows the extent of the gaps in early detection of CKD and the clear benefits of diagnosing early; INSIDE-CKD shows the unsustainable future burden of CKD and potential benefits to the healthcare system of improved management; PACE-CKD shows CKD is associated with a poorer quality of life not only for patients but also their carers; and IMPACT CKD provides modelling of the future CKD burden for public health policy planning, 包括社会和环境影响.

世界肾脏病大会(WCN)
世界肾脏病学大会(WCN)是年度科学会议, educational, 国际肾脏病学会(ISN).⁸ The ISN is a global professional association dedicated to advancing kidney health worldwide since 1960 through education, grants, research, and advocacy^.8

AstraZeneca in CVRM
心血管，肾脏和代谢 (CVRM), 澳门葡京赌博游戏的一部分, forms one of AstraZeneca’s main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys, liver and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, 并最终为再生疗法铺平道路. 公司的目标是改善和挽救数百万人的生命, by better understanding the interconnections between CVRM diseases and targeting the mechanisms that drive them, so we can detect, 更早、更有效地诊断和治疗患者. 

AstraZeneca
澳门葡京网赌游戏(LSE/STO/Nasdaq: AZN)是一家全球性制药公司, 以科学为主导的澳门葡京赌博游戏公司，专注于发现, development, 以及肿瘤学处方药的商业化, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & 新陈代谢和呼吸 & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit mushmom.net 并在社交媒体上关注公司 @AstraZeneca

Contact
有关联络投资者关系组的详情，请按 here. For Media contacts, click here. 

References

Veeva ID: Z4-63620
筹备日期:2024年4月

看看澳门葡京赌博游戏在下面的视频中做出改变会发生什么